The Brazilian National Health Surveillance Agency (Anvisa) is currently examining eight applications for semaglutide-based medications as pharmaceutical companies rush to introduce competitors to Ozempic and Wegovy, following the recent expiration of their patents. Anvisa reports a total of 17 applications under review, highlighting the competitive nature of the pharmaceutical industry in Brazil. The agency anticipates that at least one new option could be available on the market by June, promising to broaden treatment choices for patients struggling with conditions like obesity and diabetes.

The application process is chronologically structured, with five submissions currently under detailed analysis and three advanced applications waiting for responses to inquiries from Anvisa. Furthermore, nine applications are still queued for evaluation. Prominent contenders among the advanced submissions include major pharmaceutical firms such as EMS, Ávita Care, and Cristália, indicating a robust interest in capturing market share as the availability of similar medications increases. This development is likely to have significant implications for patient access to effective treatment options and could potentially reduce costs due to increased competition in the market.

As semaglutide continues to gain attention for its effectiveness in weight management and diabetes control, the successful approval and launch of these new treatments could reshape the landscape of available therapies in Brazil. The imminent emergence of generics or patent-expired competitors could drive innovation and affordability, ultimately benefiting Brazilian consumers who need these critical medications.